• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一例同时存在抗Mi-2和抗NXP-2抗体的皮肌炎病例。

A Case of Dermatomyositis Coexisting with Both Anti-Mi-2 and Anti-NXP-2 Antibodies.

作者信息

Ito Mitsuru, Moriya Chie, Matsuyama Kanako, Shu En, Hamaguchi Yasuhito, Seishima Mariko

机构信息

Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan.

Department of Molecular Pathology of Skin, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.

出版信息

Case Rep Dermatol. 2020 May 5;12(2):92-97. doi: 10.1159/000507504. eCollection 2020 May-Aug.

DOI:10.1159/000507504
PMID:32508616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7250387/
Abstract

Myositis-specific autoantibodies (MSAs) including anti-Mi-2 and anti-nuclear matrix protein 2 (NXP-2) antibodies have been detected in the patients with dermatomyositis (DM), and are useful tools for identifying clinical subsets of DM. MSAs are exclusively found in DM patients. Anti-Mi-2 antibody-positive DM patients show the typical skin lesions and myositis and are rarely associated with internal malignancy and interstitial lung disease (ILD). On the other hand, adult DM patients with anti-NXP-2 antibody often show calcinosis and internal malignancy, but rarely ILD. In addition, anti-NXP-2 antibody-positive DM patients have severe phenotype with myalgia, peripheral edema, and significant dysphagia, but with mild skin lesions. Herein, we report a rare case of classic DM coexisting with both anti-Mi-2 and anti-NXP-2 antibodies, clinically, without ILD or internal malignancy. Our patient had typical skin manifestations, muscle weakness, muscle pain, and general fatigue without calcinosis, peripheral edema, or dysphagia. Thus, the clinical phenotype was similar to anti-Mi-2 antibody-positive DM.

摘要

在皮肌炎(DM)患者中已检测到包括抗Mi-2和抗核基质蛋白2(NXP-2)抗体在内的肌炎特异性自身抗体(MSA),它们是识别DM临床亚组的有用工具。MSA仅在DM患者中发现。抗Mi-2抗体阳性的DM患者表现出典型的皮肤病变和肌炎,很少与内脏恶性肿瘤和间质性肺病(ILD)相关。另一方面,抗NXP-2抗体阳性的成年DM患者常出现钙质沉着和内脏恶性肿瘤,但很少出现ILD。此外,抗NXP-2抗体阳性的DM患者具有严重的表型,伴有肌痛、外周水肿和明显的吞咽困难,但皮肤病变较轻。在此,我们报告一例罕见的经典DM病例,同时存在抗Mi-2和抗NXP-2抗体,临床上无ILD或内脏恶性肿瘤。我们的患者有典型的皮肤表现、肌肉无力、肌肉疼痛和全身疲劳,无钙质沉着、外周水肿或吞咽困难。因此,临床表型与抗Mi-2抗体阳性的DM相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e57a/7250387/5e38904f9b1c/cde-0012-0092-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e57a/7250387/5e38904f9b1c/cde-0012-0092-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e57a/7250387/5e38904f9b1c/cde-0012-0092-g01.jpg

相似文献

1
A Case of Dermatomyositis Coexisting with Both Anti-Mi-2 and Anti-NXP-2 Antibodies.一例同时存在抗Mi-2和抗NXP-2抗体的皮肌炎病例。
Case Rep Dermatol. 2020 May 5;12(2):92-97. doi: 10.1159/000507504. eCollection 2020 May-Aug.
2
Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.抗核基质蛋白2自身抗体与皮肌炎患者的水肿、肌肉疾病及恶性肿瘤风险
Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776. doi: 10.1002/acr.23188.
3
Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.抗 NXP-2 抗体阳性的炎性肌病的临床特征及印度人群的预后。
Clin Rheumatol. 2023 Dec;42(12):3289-3297. doi: 10.1007/s10067-023-06751-0. Epub 2023 Oct 6.
4
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.特发性炎性肌病中肌炎特异性抗体的全面概述:新的和旧的生物标志物
Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19. doi: 10.1007/s12016-015-8510-y.
5
A case of vesiculobullous dermatomyositis with anti-NXP-2 antibody without malignancy.一例无恶性肿瘤的抗NXP - 2抗体阳性的水疱大疱性皮肌炎病例。
Mod Rheumatol Case Rep. 2025 Jan 16;9(1):84-87. doi: 10.1093/mrcr/rxae037.
6
Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.成人皮肌炎患者中与核基质蛋白2抗体相关的皮肤及全身表现
Arthritis Care Res (Hoboken). 2017 Dec;69(12):1909-1914. doi: 10.1002/acr.23210. Epub 2017 Nov 2.
7
Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies.皮肌炎伴抗核基质蛋白 2 抗体患者的肌周微动脉病。
Eur J Neurol. 2020 Mar;27(3):514-521. doi: 10.1111/ene.14097. Epub 2019 Oct 25.
8
Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.在使用未标记免疫沉淀检测法鉴定出核基质蛋白 2 抗体的中国成年肌炎患者中,钙沉积和恶性肿瘤较为罕见。
Clin Rheumatol. 2018 Oct;37(10):2731-2739. doi: 10.1007/s10067-018-4216-x. Epub 2018 Jul 23.
9
[Two cases of anti-nuclear matrix protein 2 antibody-positive dermatomyositis sine dermatitis with severe diffuse subcutaneous edema and dysphagia].两例抗核基质蛋白2抗体阳性的无皮肤炎皮肌炎伴严重弥漫性皮下水肿和吞咽困难
Rinsho Shinkeigaku. 2023 Nov 23;63(11):737-742. doi: 10.5692/clinicalneurol.cn-001863. Epub 2023 Oct 25.
10
[The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].[肌炎特异性抗体在多肌炎/皮肌炎相关间质性肺疾病中的临床意义]
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Aug 12;41(8):616-621. doi: 10.3760/cma.j.issn.1001-0939.2018.08.009.

引用本文的文献

1
Clinical Features of Dermatomyositis Associated with Myositis-Specific Antibodies in Moroccan Patients.摩洛哥患者中与肌炎特异性抗体相关的皮肌炎的临床特征
Clin Pract. 2025 Feb 6;15(2):31. doi: 10.3390/clinpract15020031.
2
Coexistence of Multiple Myositis-Specific Antibodies in Patients with Idiopathic Inflammatory Myopathies.特发性炎性肌病患者中多种肌炎特异性抗体的共存
J Clin Med. 2022 Nov 25;11(23):6972. doi: 10.3390/jcm11236972.

本文引用的文献

1
Four cases of anti-Mi-2 antibody-positive dermatomyositis: relationship between anti-Mi-2 antibody titre and disease severity and activity.4例抗Mi-2抗体阳性皮肌炎:抗Mi-2抗体滴度与疾病严重程度及活动度的关系
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):e233-e234. doi: 10.1111/jdv.14754. Epub 2018 Jan 5.
2
Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies.抗信号识别颗粒抗体与抗Mi-2抗体异常共存时的超急性肌无力
BMJ Case Rep. 2017 Jul 18;2017:bcr-2017-219221. doi: 10.1136/bcr-2017-219221.
3
Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.
成人皮肌炎患者中与核基质蛋白2抗体相关的皮肤及全身表现
Arthritis Care Res (Hoboken). 2017 Dec;69(12):1909-1914. doi: 10.1002/acr.23210. Epub 2017 Nov 2.
4
Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.用于检测皮肌炎中抗转录中介因子-1γ和抗Mi-2自身抗体的酶联免疫吸附测定。
J Dermatol Sci. 2016 Dec;84(3):272-281. doi: 10.1016/j.jdermsci.2016.09.013. Epub 2016 Sep 23.
5
Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.一种用于检测抗黑色素瘤分化相关基因5自身抗体的酶联免疫吸附测定法的临床应用
PLoS One. 2016 Apr 26;11(4):e0154285. doi: 10.1371/journal.pone.0154285. eCollection 2016.
6
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.特发性炎性肌病中肌炎特异性抗体的全面概述:新的和旧的生物标志物
Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19. doi: 10.1007/s12016-015-8510-y.
7
Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.皮肌炎的皮肤表现:关键临床和血清学特征——全面综述
Clin Rev Allergy Immunol. 2016 Dec;51(3):293-302. doi: 10.1007/s12016-015-8496-5.
8
Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.比较放射免疫沉淀法与抗原特异性检测法在皮肌炎患者中鉴定肌炎特异性自身抗体的效果。
Mod Rheumatol. 2014 Nov;24(6):945-8. doi: 10.3109/14397595.2014.896494. Epub 2014 Mar 26.
9
The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia.多发性肌炎和间质性肺炎中同时检测多种氨酰-tRNA 合成酶的新方法的多中心研究。
PLoS One. 2014 Jan 14;9(1):e85062. doi: 10.1371/journal.pone.0085062. eCollection 2014.
10
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.大多数癌症相关性皮肌炎患者体内存在针对核基质蛋白NXP - 2或转录中介因子1γ的抗体。
Arthritis Rheum. 2013 Nov;65(11):2954-62. doi: 10.1002/art.38093.